Jean-Paul Renaud, President & CSO, cofounderJean-Paul Renaud created the company in October 2015. He was previously CSO Science & Technology at NovAliX, an innovative drug discovery CRO (2009-2014) ; President & CEO-CSO of AliX (2002-2008), another spinoff company from IGBMC he created in 2002 (AliX’ merger with Novalyst Discovery gave birth to NovAliX in 2009) ; CNRS Research Director at IGBMC (2000-2002) ; CNRS Research Associate at IGBMC (1993-2000). He was a post-doc at the MRC Laboratory of Molecular Biology in Cambridge, UK (1987-1988). He obtained his PhD in Organic Chemistry from University Pierre & Marie Curie (Paris 6) in 1986 and an Engineering Diploma from the École Nationale Supérieure de Chimie de Paris (now Chimie ParisTech) in 1982. Jean-Paul Renaud was twice laureate of the french iLAB Contest (Concours national d’aide à la création d’entreprises de technologie innovantes) in the Creation – Development category : in 2002 for AliX and in 2017 for Urania Therapeutics, formerly called RiboStruct.
Régis Olivier, Deputy CEO & CFO
Régis Olivier brings more than 25 years of experience in finance, structuration, and management of startups. He held several positions as business analyst, controller and head of controlling in industrial companies. In 2008, he entered the medical device field as CFO for Echosens, a French startup specialized in liver disease non-invasive detection. He drove successfully the structuration and the sale of the company in 2011. In 2014, as CEO he joined Axess Vision Technology, a French startup dedicated to the development of medical single-use endoscope. He led the launch of products, the development and the structuration of the company, and found new shareholders. He holds a Master’s degree in management and finance from L’École des Cadres (EDC, Paris) obtained in 1986.